Epilepsy
GLP-1 diabetes drugs tied to modestly lower epilepsy risk in large study
An Ruwaito ta hanyar AI Hoton da AI ya samar An Binciki Gaskiya
Preliminary research published in Neurology suggests that GLP-1 medications, including drugs such as Ozempic, may be associated with a modestly lower risk of developing epilepsy in people with type 2 diabetes compared with DPP-4 inhibitors. In the analysis, GLP-1 users were 16 percent less likely to develop epilepsy after statistical adjustment, but researchers stress that the findings show an association, not proof of cause and effect.
A new study links temporal lobe epilepsy to early aging in brain support cells, showing that clearing these cells in mice reduces seizures and improves memory. Researchers at Georgetown University Medical Center used existing drugs to achieve these results, offering potential for faster treatments in humans. The findings, published on December 22, highlight hope for patients resistant to current medications.